Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dilanubicel + chemotherapy
- Development stage
- Unknown
- Lead developer
- Deverra Therapeutics
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
Dilanubicel is a universal donor, off-the-shelf, ex vivo expanded hematopoietic stem and progenitor cell (HSPC) therapy derived from pooled donor umbilical cord blood CD34+ cells. When administered following intensive chemotherapy (such as fludarabine, cyclophosphamide, and thiotepa), it acts as a non-engrafting adjuvant cell therapy to provide rapid, transient hematopoiesis and long-term immunologic benefits. The therapy is designed to enhance remission rates and improve overall survival in patients with acute myeloid leukemia (AML) and other hematologic malignancies by reducing the period of severe neutropenia and infection risk. Dilanubicel has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation, Orphan Drug Designation (ODD), and Fast Track designation for the treatment of newly diagnosed AML.
- Other names
- dilanubicelDVX101DVX-101DVX 101NLA101NLA-101NLA 101
Beyond the preview
Go deeper on dilanubicel + chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dilanubicel + chemotherapy.